-
2
-
-
84866268783
-
Management of hyperglycemia in type 2 diabetes: A patient-centered approach: Position statement of the American Diabetes Association ADA) and the European Association for the Study of Diabetes (EASD)
-
Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364-79
-
(2012)
Diabetes Care
, vol.35
, pp. 1364-1379
-
-
Inzucchi, S.E.1
Bergenstal, R.M.2
Buse, J.B.3
-
3
-
-
84871995815
-
Standards of medical care in diabetes-2013
-
American Diabetes Association
-
American Diabetes Association. Standards of medical care in diabetes-2013. Diabetes Care 2013;36(Suppl 1):S11-66
-
(2013)
Diabetes Care
, vol.36
, pp. S11-66
-
-
-
4
-
-
84857029848
-
Proportion of patients at HbA1c target >7% with eight classes of antidiabetic drugs in type 2 diabetes: Systematic review of 218 randomized controlled trials with 78 945 patients
-
Esposito K, Chiodini P, Bellastella G, et al. Proportion of patients at HbA1c target 7% with eight classes of antidiabetic drugs in type 2 diabetes: systematic review of 218 randomized controlled trials with 78 945 patients. Diabetes Obes Metab 2012;14:228-33
-
(2012)
Diabetes Obes Metab
, vol.14
, pp. 228-233
-
-
Esposito, K.1
Chiodini, P.2
Bellastella, G.3
-
5
-
-
0042168813
-
Polypharmacy and medication adherence in patients with type 2 diabetes
-
Grant RW, Devita NG, Singer DE, Meigs JB. Polypharmacy and medication adherence in patients with type 2 diabetes. Diabetes Care 2003;26:1408-12
-
(2003)
Diabetes Care
, vol.26
, pp. 1408-1412
-
-
Grant, R.W.1
Devita, N.G.2
Singer, D.E.3
Meigs, J.B.4
-
6
-
-
79951631623
-
Patient adherence to medication requirements for therapy of type 2 diabetes
-
Bailey CJ, Kodack M. Patient adherence to medication requirements for therapy of type 2 diabetes. Int J Clin Pract 2011;65:314-22
-
(2011)
Int J Clin Pract
, vol.65
, pp. 314-322
-
-
Bailey, C.J.1
Kodack, M.2
-
7
-
-
33947168360
-
Patient-reported perceptions of side effects of antihyperglycemic medication and adherence to medication regimens in persons with diabetes mellitus
-
Chao J, Nau DP, Aikens JE. Patient-reported perceptions of side effects of antihyperglycemic medication and adherence to medication regimens in persons with diabetes mellitus. Clin Ther 2007;29:177-80
-
(2007)
Clin Ther
, vol.29
, pp. 177-180
-
-
Chao, J.1
Nau, D.P.2
Aikens, J.E.3
-
8
-
-
43449100355
-
Hypoglycaemic symptoms, treatment satisfaction, adherence and their associations with glycaemic goal in patients with type 2 diabetes mellitus: Findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) Study
-
Alvarez GF, Tofe PS, Krishnarajah G, et al. Hypoglycaemic symptoms, treatment satisfaction, adherence and their associations with glycaemic goal in patients with type 2 diabetes mellitus: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) Study. Diabetes Obes Metab 2008;10(Suppl 1):25-32
-
(2008)
Diabetes Obes Metab
, vol.10
, pp. 25-32
-
-
Alvarez, G.F.1
Tofe, P.S.2
Krishnarajah, G.3
-
11
-
-
84911484318
-
-
European Medicines Agency [Last accessed 10 June 2014]
-
European Medicines Agency. Jardiance (empagliflozin) European public assessment report (EPAR). 2014. Available from: www.ema.europa.eu/docs/en-GB/document-library/EPAR-Summary-for-the-public/human/002677/WC500168595.pdf [Last accessed 10 June 2014]
-
(2014)
Jardiance (Empagliflozin) European Public Assessment Report (EPAR)
-
-
-
12
-
-
83655184724
-
Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: Characterisation and comparison with other SGLT-2 inhibitors
-
Grempler R, Thomas L, Eckhardt M, et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab 2012;14:83-90
-
(2012)
Diabetes Obes Metab
, vol.14
, pp. 83-90
-
-
Grempler, R.1
Thomas, L.2
Eckhardt, M.3
-
13
-
-
84877652575
-
Empagliflozin (BI 10773), a potent and selective SGLT-2 inhibitor, induces dosedependent glucosuria in healthy subjects
-
Seman L, Macha S, Nehmiz G, et al. Empagliflozin (BI 10773), a potent and selective SGLT-2 inhibitor, induces dosedependent glucosuria in healthy subjects. Clinical Pharm in Drug Dev 2013;2:152-61
-
(2013)
Clinical Pharm in Drug Dev
, vol.2
, pp. 152-161
-
-
Seman, L.1
MacHa, S.2
Nehmiz, G.3
-
14
-
-
84878947970
-
Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes
-
Heise T, Seewaldt-Becker E, Macha S, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes. Diabetes Obes Metab 2013;15:613-21
-
(2013)
Diabetes Obes Metab
, vol.15
, pp. 613-621
-
-
Heise, T.1
Seewaldt-Becker, E.2
MacHa, S.3
-
15
-
-
84887072459
-
Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple rising doses of empagliflozin in patients with type 2 diabetes mellitus
-
Heise T, Seman L, Macha S, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple rising doses of empagliflozin in patients with type 2 diabetes mellitus. Diabetes Ther 2013;4:331-45
-
(2013)
Diabetes Ther
, vol.4
, pp. 331-345
-
-
Heise, T.1
Seman, L.2
MacHa, S.3
-
16
-
-
84893727925
-
Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment
-
Macha S, Mattheus M, Halabi A, et al. Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment. Diabetes Obes Metab 2014;16:215-22
-
(2014)
Diabetes Obes Metab
, vol.16
, pp. 215-222
-
-
MacHa, S.1
Mattheus, M.2
Halabi, A.3
-
17
-
-
84887122313
-
Effect of food on the pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, and assessment of dose proportionality in healthy volunteers
-
Macha S, Jungnik A, Hohl K, et al. Effect of food on the pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, and assessment of dose proportionality in healthy volunteers. Int J Clin Pharmacol Ther 2013;51:873-9
-
(2013)
Int J Clin Pharmacol Ther
, vol.51
, pp. 873-879
-
-
MacHa, S.1
Jungnik, A.2
Hohl, K.3
-
18
-
-
84892478812
-
Pharmacokinetics, safety and tolerability of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with hepatic impairment
-
Macha S, Rose P, Mattheus M, et al. Pharmacokinetics, safety and tolerability of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with hepatic impairment. Diabetes Obes Metab 2013;16:118-23
-
(2013)
Diabetes Obes Metab
, vol.16
, pp. 118-123
-
-
MacHa, S.1
Rose, P.2
Mattheus, M.3
-
19
-
-
84885170468
-
Population pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with type 2 diabetes
-
Riggs MM, Staab A, Seman L, et al. Population pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with type 2 diabetes. J Clin Pharmacol 2013;53:1028-38
-
(2013)
J Clin Pharmacol
, vol.53
, pp. 1028-1038
-
-
Riggs, M.M.1
Staab, A.2
Seman, L.3
-
20
-
-
84911476493
-
Exposure-response modelling for empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in patients with type 2 diabetes
-
[Epub ahead of print] doi: 10.1111/bcp.12453
-
Riggs MM, Seman LJ, Staab A, et al. Exposure-response modelling for empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in patients with type 2 diabetes. Br J Clin Pharmacol 2014. [Epub ahead of print] doi: 10.1111/bcp.12453
-
(2014)
Br J Clin Pharmacol
-
-
Riggs, M.M.1
Seman, L.J.2
Staab, A.3
-
21
-
-
84873849619
-
Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT2) inhibitor, and metformin following coadministration in healthy volunteers
-
Macha S, Dieterich S, Mattheus M, et al. Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT2) inhibitor, and metformin following coadministration in healthy volunteers. Int J Clin Pharmacol Ther 2013;51:132-40
-
(2013)
Int J Clin Pharmacol Ther
, vol.51
, pp. 132-140
-
-
MacHa, S.1
Dieterich, S.2
Mattheus, M.3
-
22
-
-
84872381919
-
Pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 inhibitor, and glimepiride following coadministration in healthy volunteers: A randomised, open-label, crossover study
-
Macha S, Mattheus M, Pinnetti S, et al. Pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 inhibitor, and glimepiride following coadministration in healthy volunteers: a randomised, open-label, crossover study. Diabetes Res Clin Metab 2012;1:14
-
(2012)
Diabetes Res Clin Metab
, vol.1
, pp. 14
-
-
MacHa, S.1
Mattheus, M.2
Pinnetti, S.3
-
23
-
-
84872111344
-
Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT-2) inhibitor, coadministered with sitagliptin in healthy volunteers
-
Brand T, Macha S, Mattheus M, et al. Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT-2) inhibitor, coadministered with sitagliptin in healthy volunteers. Adv Ther 2012;29:889-99
-
(2012)
Adv Ther
, vol.29
, pp. 889-899
-
-
Brand, T.1
MacHa, S.2
Mattheus, M.3
-
24
-
-
84872418644
-
A randomized, open-label, crossover study to evaluate the pharmacokinetics of empagliflozin and linagliptin after coadministration in healthy male volunteers
-
Friedrich C, Metzmann K, Rose P, et al. A randomized, open-label, crossover study to evaluate the pharmacokinetics of empagliflozin and linagliptin after coadministration in healthy male volunteers. Clin Ther 2013;35:A33-42
-
(2013)
Clin Ther
, vol.35
, pp. A33-42
-
-
Friedrich, C.1
Metzmann, K.2
Rose, P.3
-
25
-
-
84874326639
-
Lack of drug-drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and warfarin in healthy volunteers
-
Macha S, Rose P, Mattheus M, et al. Lack of drug-drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and warfarin in healthy volunteers. Diabetes Obes Metab 2013;15:316-23
-
(2013)
Diabetes Obes Metab
, vol.15
, pp. 316-323
-
-
MacHa, S.1
Rose, P.2
Mattheus, M.3
-
26
-
-
84911497060
-
Pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 inhibitor, and simvastatin following co-administration in healthy volunteers
-
[Epub ahead of print]
-
Macha S, Lang B, Pinnetti S, Broedl U. Pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 inhibitor, and simvastatin following co-administration in healthy volunteers. Int J Clin Pharmacol Ther 2014. [Epub ahead of print]. doi: 10.5414/CP202117
-
(2014)
Int J Clin Pharmacol Ther
-
-
MacHa, S.1
Lang, B.2
Pinnetti, S.3
Broedl, U.4
-
27
-
-
84874966394
-
Lack of clinically relevant drug-drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and verapamil, ramipril, or digoxin in healthy volunteers
-
Macha S, Sennewald R, Rose P, et al. Lack of clinically relevant drug-drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and verapamil, ramipril, or digoxin in healthy volunteers. Clin Ther 2013;35:226-35
-
(2013)
Clin Ther
, vol.35
, pp. 226-235
-
-
MacHa, S.1
Sennewald, R.2
Rose, P.3
-
28
-
-
84896809350
-
Lack of interaction between the sodium glucose cotransporter-2 inhibitor empagliflozin and hydrochlorothiazide or torasemide in patients with T2DM
-
Giessman T, Heise T, Macha S, et al. Lack of interaction between the sodium glucose cotransporter-2 inhibitor empagliflozin and hydrochlorothiazide or torasemide in patients with T2DM. Diabetes 2012;61:abstract 2330-PO
-
(2012)
Diabetes
, vol.61
-
-
Giessman, T.1
Heise, T.2
MacHa, S.3
-
29
-
-
84894026013
-
Effect of gemfibrozil, rifampicin, or probenecid on the pharmacokinetics of the SGLT2 inhibitor empagliflozin in healthy volunteers
-
Macha S, Koenen R, Sennewald R, et al. Effect of gemfibrozil, rifampicin, or probenecid on the pharmacokinetics of the SGLT2 inhibitor empagliflozin in healthy volunteers. Clin Ther 2014;36:abstract 280-90
-
(2014)
Clin Ther
, vol.36
-
-
MacHa, S.1
Koenen, R.2
Sennewald, R.3
-
30
-
-
84879795546
-
A Phase IIb, randomized, placebocontrolled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes
-
Ferrannini E, Seman L, Seewaldt-Becker E, et al. A Phase IIb, randomized, placebocontrolled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes. Diabetes Obes Metab 2013;15:721-8
-
(2013)
Diabetes Obes Metab
, vol.15
, pp. 721-728
-
-
Ferrannini, E.1
Seman, L.2
Seewaldt-Becker, E.3
-
31
-
-
84887191925
-
Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia
-
Rosenstock J, Seman LJ, Jelaska A, et al. Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia. Diabetes Obes Metab 2013;15:1154-60
-
(2013)
Diabetes Obes Metab
, vol.15
, pp. 1154-1160
-
-
Rosenstock, J.1
Seman, L.J.2
Jelaska, A.3
-
32
-
-
84891851923
-
Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: An active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes
-
Ferrannini E, Berk A, Hantel S, et al. Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes. Diabetes Care 2013;36:4015-21
-
(2013)
Diabetes Care
, vol.36
, pp. 4015-4021
-
-
Ferrannini, E.1
Berk, A.2
Hantel, S.3
-
33
-
-
84885954870
-
Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: A randomised, double-blind, placebocontrolled, phase 3 trial
-
Roden M, Weng J, Eilbracht J, et al. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebocontrolled, phase 3 trial. Lancet Diabetes Endocrinol 2013;1:208-19
-
(2013)
Lancet Diabetes Endocrinol
, vol.1
, pp. 208-219
-
-
Roden, M.1
Weng, J.2
Eilbracht, J.3
-
34
-
-
84901455931
-
Empagliflozin as add-on to metformin in patients with type 2 diabetes: A 24-week, randomized, double-blind, placebocontrolled trial
-
HaringH-U,Merker L, Seewaldt-Becker E, et al. Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebocontrolled trial. Diabetes Care 2014;37:1650-9
-
(2014)
Diabetes Care
, vol.37
, pp. 1650-1659
-
-
Haringh-Umerker, L.1
Seewaldt-Becker, E.2
-
35
-
-
84885952950
-
Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: A 24-week randomized, doubleblind, placebo-controlled trial
-
HaringH-U,Merker L, Seewaldt-Becker E, et al. Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week randomized, doubleblind, placebo-controlled trial. Diabetes Care 2013;36:3396-404
-
(2013)
Diabetes Care
, vol.36
, pp. 3396-3404
-
-
Haringh-Umerker, L.1
Seewaldt-Becker, E.2
-
36
-
-
84892477577
-
Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: A 24-week, randomized, placebo-controlled trial
-
Kovacs CS, Seshiah V, Swallow R, et al. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial. Diabetes Obes Metab 2013;16:147-58
-
(2013)
Diabetes Obes Metab
, vol.16
, pp. 147-158
-
-
Kovacs, C.S.1
Seshiah, V.2
Swallow, R.3
-
41
-
-
84908332537
-
Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: A 104-week randomised active-controlled double-blind phase 3 trial
-
Ridderstrale M, Andersen KR, Zeller C, et al. Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial. Lancet Diabetes Endocrinol 2014;2(9):691-700
-
(2014)
Lancet Diabetes Endocrinol
, vol.2
, Issue.9
, pp. 691-700
-
-
Ridderstrale, M.1
Andersen, K.R.2
Zeller, C.3
-
42
-
-
84911486702
-
Empagliflozin (EMPA) compared with glimepiride (GLIM) as add-on to metformin (MET) for 2 years in patients with type 2 diabetes (T2DM) [abstract 266-OR]
-
Ridderstrale M, Andersen KR, Zeller C, et al. Empagliflozin (EMPA) compared with glimepiride (GLIM) as add-on to metformin (MET) for 2 years in patients with type 2 diabetes (T2DM) [abstract 266-OR]. Diabetes 2014;63(Suppl 1):A70
-
(2014)
Diabetes
, vol.63
, pp. A70
-
-
Ridderstrale, M.1
Andersen, K.R.2
Zeller, C.3
-
43
-
-
84884205365
-
Empagliflozin as add-on to basal insulin for 78 weeks improves glycemic control with weight loss in insulin-treated type 2 diabetes (T2DM) [abstract 1102-P]
-
Rosenstock J, Jelaska A, Wang F, et al. Empagliflozin as add-on to basal insulin for 78 weeks improves glycemic control with weight loss in insulin-treated type 2 diabetes (T2DM) [abstract 1102-P]. Diabetes 2013;62(Suppl 1):A285
-
(2013)
Diabetes
, vol.62
, pp. A285
-
-
Rosenstock, J.1
Jelaska, A.2
Wang, F.3
-
44
-
-
84903511385
-
Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes
-
Rosenstock J, Jelaska A, Frappin G, et al. Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes. Diabetes Care 2014;37:1815-23
-
(2014)
Diabetes Care
, vol.37
, pp. 1815-1823
-
-
Rosenstock, J.1
Jelaska, A.2
Frappin, G.3
-
45
-
-
84899961819
-
Efficacy and safety of empagliflozin added to existing anti-diabetes therapy in patients with type 2 diabetes and chronic kidney disease: A randomised, doubleblind, placebo-controlled trial
-
Barnett AH, Mithal A, Manassie J, et al. Efficacy and safety of empagliflozin added to existing anti-diabetes therapy in patients with type 2 diabetes and chronic kidney disease: a randomised, doubleblind, placebo-controlled trial. Lancet Diabetes Endocrinol 2014;2:369-84
-
(2014)
Lancet Diabetes Endocrinol
, vol.2
, pp. 369-384
-
-
Barnett, A.H.1
Mithal, A.2
Manassie, J.3
-
46
-
-
84928196614
-
Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension
-
[Epub ahead of print]
-
Tikkanen I, Narko K, Zeller C, et al. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care [Epub ahead of print]. doi:10.2337/dc14-1096
-
Diabetes Care
-
-
Tikkanen, I.1
Narko, K.2
Zeller, C.3
-
47
-
-
84892959743
-
The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus
-
Cherney DZ, Perkins BA, Soleymanlou N, et al. The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus. Cardiovasc Diabetol 2014;13:28
-
(2014)
Cardiovasc Diabetol
, vol.13
, pp. 28
-
-
Cherney, D.Z.1
Perkins, B.A.2
Soleymanlou, N.3
-
48
-
-
84898854471
-
Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: A systematic review and meta-analysis
-
Baker WL, Smyth LR, Riche DM, et al. Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis. J Am Soc Hypertens 2014;8:262-75
-
(2014)
J Am Soc Hypertens
, vol.8
, pp. 262-275
-
-
Baker, W.L.1
Smyth, L.R.2
Riche, D.M.3
-
49
-
-
84893214045
-
Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus
-
Cherney DZ, Perkins BA, Soleymanlou N, et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 2014;129:587-97
-
(2014)
Circulation
, vol.129
, pp. 587-597
-
-
Cherney, D.Z.1
Perkins, B.A.2
Soleymanlou, N.3
-
50
-
-
84911497059
-
Sodium glucose cotransporter 2 (SGLT2)inhibition with empagliflozin (EMPA) reduces microalbuminuria in patients with type 2 diabetes (T2D)
-
Cherney D, von Eynatten M, Lund S, et al. Sodium glucose cotransporter 2 (SGLT2) inhibition with empagliflozin (EMPA) reduces microalbuminuria in patients with type 2 diabetes (T2D). Diabetes 2014;63(Suppl 1): abstract 1125-P
-
(2014)
Diabetes
, vol.63
-
-
Cherney, D.1
Von Eynatten, M.2
Lund, S.3
-
51
-
-
84876938443
-
The potential of sodium glucose cotransporter 2 (SGLT2) inhibitors to reduce cardiovascular risk in patients with type 2 diabetes (T2DM)
-
Basile JN. The potential of sodium glucose cotransporter 2 (SGLT2) inhibitors to reduce cardiovascular risk in patients with type 2 diabetes (T2DM). J Diabetes Complications 2013;27:280-6
-
(2013)
J Diabetes Complications
, vol.27
, pp. 280-286
-
-
Basile, J.N.1
-
52
-
-
84902756416
-
Rationale, design, and baseline characteristics of a randomized, placebocontrolled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME)
-
Zinman B, Inzucchi SE, Lachin JM, et al. Rationale, design, and baseline characteristics of a randomized, placebocontrolled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME). Cardiovasc Diabetol 2014;13:102
-
(2014)
Cardiovasc Diabetol
, vol.13
, pp. 102
-
-
Zinman, B.1
Inzucchi, S.E.2
Lachin, J.M.3
-
53
-
-
79955752170
-
Comparative effectiveness and safety of medications for type 2 diabetes: An update including new drugs and 2-drug combinations
-
Bennett WL, Maruthur NM, Singh S, et al. Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med 2011;154:602-13
-
(2011)
Ann Intern Med
, vol.154
, pp. 602-613
-
-
Bennett, W.L.1
Maruthur, N.M.2
Singh, S.3
-
54
-
-
84868660467
-
Incidence of urinary tract infection among patients with type 2 diabetes in the UK General Practice Research Database (GPRD)
-
Hirji I, Guo Z, Andersson SW, et al. Incidence of urinary tract infection among patients with type 2 diabetes in the UK General Practice Research Database (GPRD). J Diabetes Complications 2012;26:513-16
-
(2012)
J Diabetes Complications
, vol.26
, pp. 513-516
-
-
Hirji, I.1
Guo, Z.2
Andersson, S.W.3
-
55
-
-
84868650986
-
Incidence of genital infection among patients with type 2 diabetes in the UK General Practice Research Database
-
Hirji I, Andersson SW, Guo Z, et al. Incidence of genital infection among patients with type 2 diabetes in the UK General Practice Research Database. J Diabetes Complications 2012;26:501-5
-
(2012)
J Diabetes Complications
, vol.26
, pp. 501-505
-
-
Hirji, I.1
Andersson, S.W.2
Guo, Z.3
-
56
-
-
84883799810
-
Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin
-
Johnsson KM, Ptaszynska A, Schmitz B, et al. Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin. J Diabetes Complications 2013;27:479-84
-
(2013)
J Diabetes Complications
, vol.27
, pp. 479-484
-
-
Johnsson, K.M.1
Ptaszynska, A.2
Schmitz, B.3
-
57
-
-
84900823374
-
Genital mycotic infections with canagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with type 2 diabetes mellitus: A pooled analysis of clinical studies
-
Nyirjesy P, Sobel JD, Fung A, et al. Genital mycotic infections with canagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. Curr Med Res Opin 2014;30:1109-19
-
(2014)
Curr Med Res Opin
, vol.30
, pp. 1109-1119
-
-
Nyirjesy, P.1
Sobel, J.D.2
Fung, A.3
-
58
-
-
84883810898
-
Urinary tract infections in patients with diabetes treated with dapagliflozin
-
Johnsson KM, Ptaszynska A, Schmitz B, et al. Urinary tract infections in patients with diabetes treated with dapagliflozin. J Diabetes Complications 2013;27:473-8
-
(2013)
J Diabetes Complications
, vol.27
, pp. 473-478
-
-
Johnsson, K.M.1
Ptaszynska, A.2
Schmitz, B.3
-
59
-
-
84897019959
-
Urinary tract infection in randomized phase III studies of canagliflozin, a sodium glucose co-transporter 2 inhibitor
-
Nicolle LE, Capuano G, Fung A, Usiskin K. Urinary tract infection in randomized phase III studies of canagliflozin, a sodium glucose co-transporter 2 inhibitor. Postgrad Med 2014;126:7-17
-
(2014)
Postgrad Med
, vol.126
, pp. 7-17
-
-
Nicolle, L.E.1
Capuano, G.2
Fung, A.3
Usiskin, K.4
-
60
-
-
84911490634
-
No overall increase in volume depletion events with empagliflozin (EMPA) in a pooled analysis of more than 11,000 patients with type 2 diabetes (T2DM) [abstract SA-PO373]
-
Toto R, Wanner C, Gerich J, et al. No overall increase in volume depletion events with empagliflozin (EMPA) in a pooled analysis of more than 11,000 patients with type 2 diabetes (T2DM) [abstract SA-PO373]. J Am Soc Nephrol 2013;24:711A
-
(2013)
J Am Soc Nephrol
, vol.24
, pp. 711A
-
-
Toto, R.1
Wanner, C.2
Gerich, J.3
-
61
-
-
84899941589
-
Empagliflozin improves glycemic parameters and cardiovascular risk factors in patients with type 2 diabetes (T2DM): Pooled data from four pivotal Phase III trials [abstract 69-LB]
-
Hach T, Gerich J, Salsali A, et al. Empagliflozin improves glycemic parameters and cardiovascular risk factors in patients with type 2 diabetes (T2DM): pooled data from four pivotal Phase III trials [abstract 69-LB]. Diabetes 2013;62(Suppl 1A):LB19
-
(2013)
Diabetes
, vol.62
, pp. LB19
-
-
Hach, T.1
Gerich, J.2
Salsali, A.3
-
62
-
-
55949096514
-
SLC2A9 is a high-capacity urate transporter in humans
-
Caulfield MJ, Munroe PB, O'Neill D, et al. SLC2A9 is a high-capacity urate transporter in humans. PLoS Med 2008;5:e197
-
(2008)
PLoS Med
, vol.5
, pp. e197
-
-
Caulfield, M.J.1
Munroe, P.B.2
O'Neill, D.3
|